一名急性早幼粒细胞白血病患者的髓外复发：三氧化二砷、全反式维甲酸和吉妥单抗奥唑米星治疗成功
Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.
作者信息
Tsimberidou Apostolia-Maria, Estey Elihu, Whitman Gary J, Dryden Mark J, Ratnam Suresh, Pierce Sherry, Faderl Stefan, Giles Francis, Kantarjian Hagop M, Garcia-Manero Guillermo
机构信息
Department of Leukemia, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston 77030, USA.
出版信息
Leuk Res. 2004 Sep;28(9):991-4. doi: 10.1016/j.leukres.2004.01.004.
Acute promyelocytic leukemia (APL) is characterized by the presence of the t(15;17) translocation, resulting in the PML-RAR fusion protein. Standard treatment consists of the combination of all-trans retinoic acid (ATRA) with an anthracycline that results in complete remission (CR) rates in excess of 90%. Recently, several new agents have been shown to have clinical activity in APL. These include a liposomal formulation of ATRA (lipo-ATRA), and gemtuzumab ozogamicin (GO). Herein, we report a patient with APL who relapsed with extramedullary disease 2.5 years after lipo-ATRA therapy and was successfully treated with the sequence of A2O3, ATRA, and GO and we summarize our experience with patients with isolated extramedullary relapse in APL.
急性早幼粒细胞白血病（APL）的特征是存在t(15;17)易位，导致PML-RAR融合蛋白。标准治疗包括全反式维甲酸（ATRA）与蒽环类药物联合使用，其完全缓解（CR）率超过90%。最近，几种新药已显示在APL中具有临床活性。这些药物包括ATRA的脂质体制剂（lipo-ATRA）和吉妥珠单抗奥唑米星（GO）。在此，我们报告1例APL患者，其在接受lipo-ATRA治疗2.5年后出现髓外疾病复发，并先后接受A2O3、ATRA和GO治疗成功缓解，同时我们总结了对APL孤立性髓外复发患者的治疗经验。
Zotero 插件